US009408895B2

(12) **United States Patent**
Fallon

(10) **Patent No.: US 9,408,895 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **METHOD OF TREATING PREGNANCY-INDUCED HYPERTENSION**

(71) Applicant: **Curemark, LLC**, Rye, NY (US)

(72) Inventor: **Joan M. Fallon**, Bronxville, NY (US)

(73) Assignee: **CUREMARK, LLC**, Rye, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/640,385**

(22) Filed: **Mar. 6, 2015**

(65) **Prior Publication Data**

US 2015/0174220 A1 Jun. 25, 2015

Related U.S. Application Data

(62) Division of application No. 14/037,696, filed on Sep. 26, 2013, which is a division of application No. 12/047,818, filed on Mar. 13, 2008, now Pat. No. 8,658,163.

(51) **Int. Cl.**

A61K 38/00	(2006.01)
A61K 38/54	(2006.01)
A61K 36/185	(2006.01)
A61K 38/47	(2006.01)
A61K 38/48	(2006.01)
A61K 38/46	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 38/54*** (2013.01); ***A61K 36/185*** (2013.01); ***A61K 38/465*** (2013.01); ***A61K 38/47*** (2013.01); ***A61K 38/48*** (2013.01); ***A61K 38/4826*** (2013.01); ***A61K 38/4873*** (2013.01); *C12Y 302/01* (2013.01); *C12Y 304/21001* (2013.01); *C12Y 304/21004* (2013.01); *C12Y 304/22002* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,002,883	A	10/1961	Butt et al.
3,223,594	A	12/1965	Serge
3,322,626	A	5/1967	D'Argento
3,357,894	A	12/1967	Jose et al.
3,515,642	A	6/1970	Mima et al.
3,574,819	A	4/1971	Gross et al.
3,860,708	A	1/1975	Prout
3,940,478	A	2/1976	Kurtz
4,079,125	A	3/1978	Sipos
4,145,410	A	3/1979	Sears
4,241,046	A	12/1980	Papahadjopoulos et al.
4,280,971	A	7/1981	Wischniewski et al.
4,447,412	A	5/1984	Bilton
4,456,544	A	6/1984	Lupova et al.
4,623,624	A	11/1986	Schultze
4,826,679	A	5/1989	Roy
5,190,775	A	3/1993	Klose
5,250,418	A	10/1993	Moller et al.
5,324,514	A	6/1994	Sipos
5,378,462	A	1/1995	Boedecker et al.
5,436,319	A	7/1995	Kung et al.
5,437,319	A	8/1995	Garuglieri
5,439,935	A	8/1995	Rawlings et al.
5,460,812	A	10/1995	Sipos
5,476,661	A	12/1995	Pillai et al.
5,527,678	A	6/1996	Blaser et al.
5,585,115	A	12/1996	Sherwood et al.
5,607,863	A	3/1997	Chandler
5,648,335	A	7/1997	Lewis et al.
5,674,532	A	10/1997	Atzl et al.
5,686,311	A	11/1997	Shaw
5,750,104	A	5/1998	Sipos
5,776,917	A	7/1998	Blank et al.
5,858,758	A	1/1999	Hillman et al.
5,952,178	A	9/1999	Lapidus et al.
5,958,875	A	9/1999	Longo et al.
5,977,175	A	11/1999	Lin
5,985,891	A	11/1999	Rowe
6,011,001	A	1/2000	Navia et al.
6,013,286	A	1/2000	Klose
6,020,310	A	2/2000	Beck et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2198317	A1	2/1997
CA	2263703	A1	8/1999

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 14/693,711, filed Apr. 22, 2015, Fallon.
U.S. Appl. No. 14/713,178, filed May 15, 2015, Fallon.
U.S. Appl. No. 14/713,221, filed May 15, 2015, Fallon et al.
U.S. Appl. No. 14/713,242, filed May 15, 2015, Fallon et al.
Fliri, et al. Drug effects viewed from a signal transduction network perspective. J Med Chem. Dec. 24, 2009;52(24):8038-46. doi: 10.1021/jm901001p.
Mizutani, et al. Effects of placental proteases on maternal and fetal blood pressure in normal pregnancy and preeclampsia. Am J Hypertens. Jun. 1996;9(6):591-7.
NIH, "Celiac Disease", National Digestive Diseases Information Clearinghouse: Bethesda, MD, 2008; 12 pages.
Notice of allowance dated Apr. 3, 2015 for U.S. Appl. No. 13/737,225.

(Continued)

Primary Examiner — Hope Robinson

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.

12 Claims, 4 Drawing Sheets